Vanguard Group Inc. Raises Stock Holdings in Harrow, Inc. $HROW

Vanguard Group Inc. grew its stake in Harrow, Inc. (NASDAQ:HROW) by 2.7% during the 4th quarter, Holdings Channel reports. The fund owned 1,921,683 shares of the company’s stock after acquiring an additional 50,889 shares during the period. Vanguard Group Inc. owned about 0.05% of Harrow worth $94,162,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Harrow in the second quarter valued at $48,000. State of Alaska Department of Revenue purchased a new stake in shares of Harrow in the third quarter valued at $83,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after buying an additional 369 shares during the period. Tower Research Capital LLC TRC lifted its position in Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after buying an additional 2,615 shares during the period. Finally, Larson Financial Group LLC lifted its position in Harrow by 848.2% during the third quarter. Larson Financial Group LLC now owns 2,162 shares of the company’s stock worth $104,000 after buying an additional 1,934 shares during the period. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Weiss Ratings downgraded Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Harrow in a research report on Thursday, March 19th. B. Riley Financial reiterated a “buy” rating and set a $65.00 target price (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. BTIG Research reiterated a “buy” rating and set a $63.00 target price on shares of Harrow in a research report on Tuesday. Finally, Cantor Fitzgerald reduced their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $69.43.

Harrow Stock Performance

NASDAQ HROW opened at $29.83 on Thursday. The business’s 50-day moving average price is $36.83 and its 200 day moving average price is $42.26. Harrow, Inc. has a twelve month low of $24.62 and a twelve month high of $54.85. The company has a market capitalization of $1.11 billion, a PE ratio of -72.75 and a beta of 0.34. The company has a current ratio of 2.48, a quick ratio of 2.06 and a debt-to-equity ratio of 10.30.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.During the same quarter last year, the business earned ($0.38) earnings per share. On average, research analysts predict that Harrow, Inc. will post 0.48 earnings per share for the current year.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.